Tumor Microenvironment Can Predict Chemotherapy Response of Patients with Triple-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy
Open Access
- 15 January 2024
- journal article
- research article
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 56 (1) , 162-177
Abstract
Purpose Triple-negative breast cancer (TNBC) is a breast cancer subtype that has poor prognosis and exhibits a unique tumor microenvironment. Analysis of the tumor microbiome has indicated a relationship between the tumor microenvironment and treatment response. Therefore, we attempted to reveal the role of the tumor microbiome in patients with TNBC receiving neoadjuvant chemotherapy.Materials and Methods We collected TNBC patient RNA-sequencing samples from the Gene Expression Omnibus and extracted microbiome count data. Differential and relative abundance were estimated with linear discriminant analysis effect size. We calculated the immune cell fraction with CIBERSORTx and conducted survival analysis using the Cancer Genome Atlas patient data. Correlations between the microbiome and immune cell compositions were analyzed and a prediction model was constructed to estimate drug response.Results Among the pathological complete response group (pCR), the beta diversity varied considerably; consequently, 20 genera and 24 species were observed to express a significant differential and relative abundance. Pandoraea pulmonicola and Brucella melitensis were found to be important features in determining drug response. In correlation analysis, Geosporobacter ferrireducens, Streptococcus sanguinis, and resting natural killer cells were the most correlated factors in the pCR, whereas Nitrosospira briensis, Plantactinospora sp. BC1, and regulatory T cells were key features in the residual disease group.Conclusion Our study demonstrated that the microbiome analysis of tumor tissue can predict chemotherapy response of patients with TNBC. Further, the immunological tumor microenvironment may be impacted by the tumor microbiome, thereby affecting the corresponding survival and treatment response.Keywords
Funding Information
- National Research Foundation of Korea (2018R1A5A2023879)
- Korea Health Industry Development Institute
- Ministry of Health and Welfare (HI22C1377)
- Pusan National University Yangsan Hospital (30-2020-011)
This publication has 38 references indexed in Scilit:
- Triple-negative breast cancer risk in women is defined by the defect of estrogen signaling: preventive and therapeutic implicationsOncoTargets and Therapy, 2014
- phyloseq: An R Package for Reproducible Interactive Analysis and Graphics of Microbiome Census DataPLOS ONE, 2013
- Breast-Conserving Surgery After Tumor Downstaging by Neoadjuvant Chemotherapy is Oncologically Safe for Stage III Breast Cancer PatientsAnnals of Surgical Oncology, 2013
- CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancerBreast Cancer Research, 2012
- CD8+ cytotoxic T cell and FOXP3+ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypesBreast Cancer Research and Treatment, 2011
- Metagenomic biomarker discovery and explanationGenome Biology, 2011
- A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast CancerJAMA, 2011
- Basal-Like Breast Cancer: A Critical ReviewJournal of Clinical Oncology, 2008
- GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductorBioinformatics, 2007
- Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction NetworksGenome Research, 2003